ArticleBMC microbiology2017
The altered gut microbiota in adults with cystic fibrosis.
Article in BMC microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 101 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
101 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Functional variants in the cystic fibrosis transmembrane conductance regulator (CFTR) gene are associated with increased risk of colorectal cancer.Human molecular genetics · 2025Pooled it
- Prebiotics for people with cystic fibrosis.The Cochrane database of systematic reviews · 2023Pooled it
- Cystic Fibrosis-Related Gut Dysbiosis: A Systematic Review.Digestive diseases and sciences · 2023Pooled it
- Probiotics for people with cystic fibrosis.The Cochrane database of systematic reviews · 2020Pooled it
- Gut Bifidobacteria enrichment following oral Lactobacillus-supplementation is associated with clinical improvements in children with cystic fibrosis.BMC pulmonary medicine · 2022Trial
- Effects of Bifidobacterium animalis ssp. lactis 420 on gastrointestinal inflammation induced by a nonsteroidal anti-inflammatory drug: A randomized, placebo-controlled, double-blind clinical trial.British journal of clinical pharmacology · 2021Trial
- The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin.Journal of gastroenterology · 2019Trial
- Bolus Weekly Vitamin D3 Supplementation Impacts Gut and Airway Microbiota in Adults With Cystic Fibrosis: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial.The Journal of clinical endocrinology and metabolism · 2018Trial
- A genotoxin associated with colorectal cancer linked to gut dysbiosis in children with cystic fibrosis.Journal of bacteriology · 2026Article
- The Gut-Lung Microbiome Crosstalk and Pulmonary Disease.Biomolecules · 2026Review
- The regional landscape of the human colon culturome in health and cystic fibrosis.Microbiology spectrum · 2026Article
- ENHANCE: a community partnership charting the evolution of early-life cystic fibrosis disease manifestations in a new era of management.ERJ open research · 2026Article
- Lactiplantibacillus plantarum GUANKE Alleviates Intestinal Barrier Damage Caused by Influenza Infection in Mice.Probiotics and antimicrobial proteins · 2026Article
- Hidden connection: Impact of the gut microbiota on respiratory diseases in children (Review).Molecular medicine reports · 2026Review
- The Gut Microbiome and Metabolomics Profiles of Dust-exposed Rats.Combinatorial chemistry & high throughput screening · 2026Article
- Assessment of the Isolated and Combined Impact of β-Glucan andNutrients · 2025Article
- A systematic longitudinal study of microbiome: integrating temporal-spatial dimensions with causal and deep learning models.BMC genomics · 2025Article
- TheMicroorganisms · 2025Review
- Profiling bile acids in the stools of humans and animal models of cystic fibrosis.Microbiology spectrum · 2025Article
- The Regional Landscape of the Human Colon Culturome in Health and Cystic Fibrosis.bioRxiv : the preprint server for biology · 2025Article
41 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCystic Fibrosis (CF) is an autosomal recessive disease that affects the function of a number of organs, principally the lungs, but also the gastrointestinal tract. The manifestations of cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction in the gastrointestinal tract, as well as frequent antibiotic exposure, undoubtedly disrupts the gut microbiota. To analyse the effects of CF and its management on the microbiome, we compared the gut microbiota of 43 individuals with CF during a period of stability, to that of 69 non-CF controls using 454-pyrosequencing of the 16S rRNA gene. The impact of clinical parameters, including antibiotic therapy, on the results was also assessed.
resultsThe CF-associated microbiome had reduced microbial diversity, an increase in Firmicutes and a reduction in Bacteroidetes compared to the non-CF controls. While the greatest number of differences in taxonomic abundances of the intestinal microbiota was observed between individuals with CF and the healthy controls, gut microbiota differences were also reported between people with CF when grouped by clinical parameters including % predicted FEV
conclusionsThis is one of the largest single-centre studies on gut microbiota in stable adults with CF and demonstrates the significantly altered gut microbiota, including reduced microbial diversity seen in CF patients compared to healthy controls. The data show the impact that CF and it's management have on gut microbiota, presenting the opportunity to develop CF specific probiotics to minimise microbiota alterations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.